What the FDA labels say about taking them together
Insulin glulisine and octreotide
Insulin glulisine's FDA label of November 25, 2025 names octreotide in its drug interactions section; octreotide's label does not name insulin glulisine itself but warns about its class (insulin analogs). The insulin glulisine label: “… inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when …”
Check it at the source: the insulin glulisine FDA label on DailyMed (effective November 25, 2025); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the insulin glulisine label say about octreotide?
Insulin glulisine label, drug interactionsDrugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.
Source: FDA drug label (Apidra), sanofi-aventis U.S. LLC, effective November 25, 2025 (SPL set e7af6a7a-8046-4fb4-9979-4ec4230b23aa), via openFDA; the full label on DailyMed
What does the octreotide label say about insulin glulisine?
Octreotide's label does not name insulin glulisine itself; it warns about its class (insulin analogs):
Octreotide label, drug interactionsCyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. ( 7 ) Lutetium Lu 177
Octreotide label, drug interactionsOctreotide inhibits the secretion of insulin and glucagon.
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin glulisine | Octreotide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $8.16 per mL 100 unit/mL vial | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once